Sustainability of a multiple rlsk factor intervention on cardiovascular disease in high-risk African American families

Ethnicity and Disease

Volumn 18, Issue 2, 2008, Pages 169-175

  Cene, Crystal W ^a   Yanek, Lisa R ^a   Moy, Taryn F ^a   Levine, David M ^a   Becker, Lewis C ^a   Becker, Diane M ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

African Americans; Cardiovascular Disease; Community Participation; Hypertension; Prevention; Risk Factors; Sustainability

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AFRICAN AMERICAN; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMMUNITY HEALTH NURSING; CONTROL GROUP; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE PREDISPOSITION; FEMALE; HEALTH AUXILIARY; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NURSE PRACTITIONER; RISK FACTOR; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; ETHNOLOGY; FOLLOW UP; INTERVENTION STUDY; MIDDLE AGED; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIAL; SIBLING; SMOKING; STATISTICS; UNITED STATES;

ADULT; AFRICAN AMERICANS; BALTIMORE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COMMUNITY HEALTH SERVICES; DISEASE SUSCEPTIBILITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERVENTION STUDIES; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; RISK FACTORS; SIBLINGS; SMOKING; SMOKING CESSATION;

EID: 47749122255     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Wood D, Joint European Societies Task Force. Established and emerging cardiovascular risk factors. Am Heart J. 2001;141:S49-57.
2. Rissanen AM. Familial occurrence of coronary heart disease: effect of age at diagnosis. Am J Cardiol. 1979;44:60-66.
3. Williams RR. Nature, nurture, and family predisposition. N Engl J Med. 1988:318: 769-771.
4. Rocimi C, Cooper R, Cao G, Sundarum C, McGee D. Familial aggregation of cardiovascular diseases in African American pedigrees. Genet Epidemiol. 1994; 11:397-407.
5. Becker DM, Yook RM, Moy TF, Blumenthal RS, Becker LC. Markedly high prevalence of coronary risk factors in apparently healthy African American and White siblings of persons with premature coronary heart disease. Am J Cardiol. 1998;82:1046-1051.
6. Becker DM, Raqueno JV, Yook RM, et al. Nurse-mediated cholesterol management compared with enhanced primary care in siblings of individuals with premature coronary disease. Arch Intern Med. 1998;158:1533-1539.
7. Allen JK, Scott LB. Alternative models in the delivery of primary and secondary prevention programs.J Cardiovasc Nurs. 2003; 18:150- 156.
8. Becker DM, Yanek LR, Johnson WR Jr, et al. Impact of a community-based multiple risk factor intervention on cardiovascular risk in Black families with a history of premature coronary disease. Circulation. 2005; 111:1298- 1304.
9. Holme I, Haaheim LL, Tonstad S, Hjermann I. Effect of dietary and antismoking advice on the incidence of myocardial infarction: a 16- year follow-up of the Oslo diet and antismoking study after its close. Nutr Metah Cardiovasc Dis. 2006;16:330-338.
10. Hypertension Detection and Follow-Up Program Cooperative Group. Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-Up Program. JAMA. 1988;259: 2113-2122.
11. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA. 1982;248:U65-1477.
12. Perloff D, Grim C, Flack J, et al. Human blood pressure determination by sphygmomanometry. Circulation. 1993;88:2460-2470.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
14. Executive summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholescerol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
15. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med. 1997; 157:2413- 2446.
16. Agency for Healthcare Research and Quality. Treating Tobacco Use and Dependence: Clinical Practice Guidelines. Washington: US Department of Health and Human Services, Public Health Services; 2000.
17. Willett JB. Measuring change: what individual growth modeling buys you. In: Amsel E, Renninger KA, eds. Change and Development: Issues of Theory, Method and Application. Lawrence Erlbaum Associates, 1997;213-243.
18. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44:1049- 1060.
19. Haskell WL, Berra K, Arias E, et al. Multifactor cardiovascular disease risk reduction in medically underserved, high-risk patients. Am J Cardiol. 2006;98:1472-1479.
20. Ellingsen I, Hjerkinn EM, Arnesen H, Seljeflot I, Hjermann I, Tonstad S. Follow-up of diet and cardiovascular risk factors 20 years after cessation of intervention in the Oslo diet and antismoking study. Eur J Clin Nutr. 2006;60: 378-385.
21. Ebrahim S, Smith GD. Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease. BMJ. 1997;314:1666-1674.
22. Steyn K, Steyn M, Swanepoel AS, et al. Twelve-year results of the coronary risk factor study (CORIS). Int J Epidemiol. 1997;26:964- 971.
23. Dennison CR, Post WS, Kim MT, et al. Underserved urban African American men: hypertension trial outcomes and mortality during 5 years. Am J Hypertens. 2007;20:164- 171.
24. Levine DM, Bone LR, Hill MN, et al. The effectiveness of a community/academic health center partnership in decreasing the level of blood pressure in an urban African American population. Ethn Dis. 2003;13:354-361.
25. Cutler JA, Grandits GA, Grimm RH Jr, Thomas HE Jr, Billings JH, Wright NH. Risk factor changes after cessation of intervention in the multiple risk factor intervention trial. The
26. MRFIT research group. Prev Med. 1991;20: 183-196.
27. Kornitzer M, De Backer G, Dramaix M, et al. Belgian heart disease prevention project: incidence and mortality results. Lancet. 1983;1:1066-1070.
28. Johnson ML, Pietz K, Battleman DS, Beyth RJ. Therapeutic goal attainment in patients with hypertension and dyslipidemia. Med Care. 2006;44:39-46.
29. Yood MU, McCarthy BD, Kempf J, et al. Racial differences in reaching target low- density lipoprotein goal among individuals treated with prescription statin therapy. Am Heart J. 2006;152:777-784.
30. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L- TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low- density lipoprotein cholesterol goals. Arch Intern Med. 2000; 160:459-67.
31. Chong PH, Tzallas-Pontikes PJ, Seeger JD, Stamos TD. The low-density lipoprotein cholesterol-lowering effect of pravastatin and factors associated with achieving targeted low- density lipoprotein levels in an African American population. Pharmacotherapy. 2000; 20:1454-1463.
32. Shaya FT, Gu A, Saunders E. Addressing cardiovascular disparities through community interventions. Ethn Dis. 2006;16:138-144.